• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    6/4/25 4:30:40 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email
    8-K
    false 0001478242 0001478242 2025-06-04 2025-06-04
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 4, 2025

     

     

    IQVIA HOLDINGS INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-35907   27-1341991

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2400 Ellis Road

    Durham, North Carolina

      27703
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (919) 998-2000

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Title of Each Class

     

    Trading

    Symbol

     

    Name of Each Exchange

    on which Registered

    Common Stock, par value $0.01 per share   “IQV”   New York Stock Exchange

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01

    Entry into a Material Definitive Agreement

    Notes Offering and Notes Indentures

    On June 4, 2025, IQVIA Inc. (the “Issuer”), a wholly owned subsidiary of IQVIA Holdings Inc. (the “Company”), completed the issuance and sale of $2,000,000,000 in gross proceeds of 6.250% senior notes due 2032 (the “Notes”).

    The Notes were issued pursuant to an Indenture, dated June 4, 2025 (the “Indenture”), among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the Notes, and certain subsidiaries of the Issuer as guarantors.

    The net proceeds from the notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to this offering, with any excess proceeds used for other general corporate purposes.

    The Notes are unsecured obligations of the Issuer, will mature on June 1, 2032, unless earlier repurchased or redeemed in accordance with their terms, and will bear interest at the rate of 6.250% per year, with interest payable semi-annually on June 1 and December 1 of each year, beginning on December 1, 2025.

    The Issuer may redeem the Senior Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to June 1, 2028 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 3.125% to 0.000%.

    The foregoing description of the Notes and the Indenture is qualified in its entirety by reference to the Indenture relating thereto, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K.

     

    Item 2.03

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

    The information set forth above under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits.

     

    Exhibit
    No.

      

    Description

    4.1    Indenture, dated June 4, 2025, among IQVIA Inc., as Issuer, U.S. Bank Trust Company, National Association, as trustee of the Notes and certain subsidiaries of the Issuer as guarantors.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: June 4, 2025

     

    IQVIA HOLDINGS INC.
    By:  

    /s/ Eric M. Sherbet

      Eric M. Sherbet
      Executive Vice President, General Counsel and Secretary
    Get the next $IQV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    2/3/2025Buy → Neutral
    BTIG Research
    12/20/2024$250.00Overweight
    Stephens
    10/14/2024Buy
    Redburn Atlantic
    9/4/2024$275.00Outperform
    RBC Capital Mkts
    7/24/2024$266.00 → $242.00Buy → Hold
    Jefferies
    6/6/2024$270.00Buy
    Goldman
    More analyst ratings

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IQVIA Announces Pricing of Senior Notes

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2032 (the "Notes"). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The Notes will mature on June 1, 2032, unless earlier repurchased or redeemed in accordance with their terms. The Notes will bear interest at a rate of 6.250% per annum and will pay interest semi-annually in arrears on J

      6/2/25 4:37:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Announces Offering of Senior Notes

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the "Notes"). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solic

      6/2/25 8:10:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

      Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas, May 27, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.

      5/27/25 7:00:00 AM ET
      $IQV
      $RNTX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IQV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IQV
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      8/15/24 7:57:23 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      2/14/24 4:11:54 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by IQVIA Holdings Inc. (Amendment)

      SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

      1/25/24 4:59:33 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      2/7/25 7:03:59 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Richard Staub III President of Research & Development Solutions

      IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

      9/25/23 8:01:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

      IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

      6/7/22 8:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

      3/14/22 9:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Financials

    Live finance-specific insights

    See more
    • IQVIA Reports First-Quarter 2025 Results

      Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

      5/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

      4/21/25 4:15:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance

      Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency TAS Revenue of $1,658 million fo

      2/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IQVIA downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00

      4/25/25 8:30:17 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by Barclays with a new price target

      Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00

      4/10/25 8:49:29 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by BTIG Research

      BTIG Research downgraded IQVIA from Buy to Neutral

      2/3/25 8:45:01 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wims Morris Leslie

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:51:44 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Goggins Colleen A

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:51:17 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Fasano Jim

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:50:50 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    SEC Filings

    See more
    • IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      6/4/25 4:30:40 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 8-K filed by IQVIA Holdings Inc.

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      6/2/25 5:22:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by IQVIA Holdings Inc.

      SCHEDULE 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

      5/9/25 11:41:43 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care